Market Place
Sourcing Support
Posluma Results In Recurrent Prostate Cancer Presented At ASTRO
01 Oct 2024 //
BUSINESSWIRE
Blue Earth Highlights POSLUMA® Data at ASTRO Annual Meeting
24 Sep 2024 //
BUSINESSWIRE
Blue Earth Diagnostics Reports POSLUMA® Performance In Prostate Cancer
30 Jul 2024 //
BUSINESSWIRE
Blue Earth Diagnostics Supports CMS Proposal For Radiopharmaceuticals
15 Jul 2024 //
BUSINESSWIRE
Blue Earth Diagnostics Names Marco Campione CEO To Lead Growth Phase
08 Jul 2024 //
BUSINESSWIRE
Blue Earth Diagnostics Highlights Results Of Studies Evaluating Impact Of
10 Jun 2024 //
BUSINESSWIRE
Blue Earth Diagnostics: Agreement with Siemens Healthineers
08 May 2024 //
BUSINESSWIRE
Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA
25 Jan 2024 //
BUSINESSWIRE
Philochem & Blue Earth Announce Three Patients Imaged in Ph 1 of 68Ga-OncoFAP
04 Dec 2023 //
GLOBENEWSWIRE
Blue Earth Announces Publication of Post-hoc Analysis Evaluating POSLUMA
28 Nov 2023 //
BUSINESSWIRE
Blue Earth Diagnostics Ltd Collaborates with Sinotau Pharmaceutical Group
17 Oct 2023 //
BUSINESSWIRE
Data on POSLUMA in Patients with Biochemical Recurrence of Prostate Cancer
02 Oct 2023 //
BUSINESSWIRE
Blue Earth AnnouncesTransitional Pass-Through Payment Reimbursement Code
26 Sep 2023 //
BUSINESSWIRE
Blue Earth Announces Addition of POSLUMA to NCCN Clinical Practice Guidelines
25 Jul 2023 //
BUSINESSWIRE
Blue Earth Diagnostics Announces Additional Results from Ph3 SPOTLIGHT Trial
29 Apr 2023 //
BUSINESSWIRE
Blue Earth Diagnostics Announces Results from PIII Trial of Agent 18F-rhPSMA-7.3
16 Feb 2023 //
BUSINESSWIRE
Blue Earth Highlights Presentation from PIII LIGHTHOUSE Study of 18F-rhPSMA-7.3
09 Feb 2023 //
BUSINESSWIRE
Blue Earth Announces Results from PIII LIGHTHOUSE Trial of18F-rhPSMA-7.3
01 Dec 2022 //
BUSINESSWIRE
Blue Earth Diagnostics Highlights Presentations on Axumin
22 Nov 2022 //
BUSINESSWIRE
Blue Earth Highlights Presentation of Results from Phase 3 LIGHTHOUSE Study
21 Nov 2022 //
BUSINESSWIRE
Blue Earth Announces Agreement with Siemens & University Hospital of TUM
18 Oct 2022 //
BUSINESSWIRE
Blue Earth Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3
27 Sep 2022 //
BUSINESSWIRE
Blue Earth Announces Reproducibility Results from PIII Trial of 18F-rhPSMA-7.3
15 Jun 2022 //
BUSINESSWIRE
Blue Earth to Present on rhPSMA Radiopharmaceuticals & 18F-Fluciclovine
09 Jun 2022 //
BUSINESSWIRE
Blue Earth Diagnostic Shows Additional Results from PIII Trial of 18F-rhPSMA-7.3
13 May 2022 //
BUSINESSWIRE
Blue Earth Diagnostics Highlights Presentation from Phase 3 SPOTLIGHT Study
01 Feb 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.